A Study of Herceptin (Trastuzumab) in Combination With Avastin (Bevacizumab) and Sequential Xeloda (Capecitabine) or Docetaxel in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer
Status: WITHDRAWN
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: bevacizumab [Avastin]|DRUG: capecitabine [Xeloda]|DRUG: docetaxel|DRUG: trastuzumab [Herceptin]
Sponsor: Hoffmann-La Roche